An evaluation of CI-564 against blood-induced chlorguanide-sensitive and chlorguanide-resistant strains of vivax malaria.
D000962:Antimalarials / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D010966:Plasmodium vivax / Q000187:drug effects*; D002727:Proguanil / Q000627:therapeutic use*; D013450:Sulfones / Q000627:therapeutic use*
D000962:Antimalarials; D013450:Sulfones; D002727:Proguanil